A randomized, cross-over trial of once-daily versus twice-daily parathyroid hormone 1-34 in treatment of hypoparathyroidism.
A randomized, cross-over trial of once-daily versus twice-daily parathyroid hormone 1-34 in treatment of hypoparathyroidism.
复制标题
每日一次与每日两次甲状旁腺激素 1-34 治疗甲状旁腺功能减退症的随机、交叉试验。
DOI:
10.1210/jcem.83.10.5185
复制
发表时间:
1998
期刊:
影响因子:
--
通讯作者:
G. Cutler
中科院分区:
文献类型:
--
作者:
K. Winer;J. Yanovski;Babak Sarani;G. Cutler
Once-daily sc injection of PTH 1-34 can normalize mean serum and urine calcium levels in patients with hypoparathyroidism; however, once-daily PTH has diminishing effects on serum calcium after 12 h, such that serum calcium levels fall below the normal range in some patients. Once-daily PTH also causes a marked increase in bone turnover, with persistent increases in markers of bone formation and resorption. To test the hypothesis that a twice-daily PTH regimen can produce more physiological control than a once-daily regimen, we performed a randomized cross-over trial, lasting 28 weeks, in 17 adult subjects with hypoparathyroidism. Each 14-week study arm was divided into a 2-week inpatient dose-adjustment phase and a 12-week outpatient phase. The PTH dose (given sc once daily at 0900 h or twice daily with one dose at 0900 h and the other at 2100 h) was adjusted to maintain both serum and urine calcium within, or close to, the normal range. During the second half of the day (12-24 h), twice-daily PTH increased serum calcium and magnesium levels more effectively than once-daily PTH. In patients with calcium receptor mutations (CaR), once-daily PTH normalized urine calcium, provided that serum calcium was maintained at levels below normal range. However, twice-daily PTH treatment produced higher mean serum calcium in patients with CaR with no significant rise in urine calcium excretion, and with no significant differences in either serum or urine calcium levels between CaR and patients with acquired or idiopathic hypoparathyroidism. Thus, treatment with twice-daily PTH is the better regimen for patients with CaR to overcome their tendency to hypercalciuria while producing near-normal levels of serum calcium. The total daily PTH dose was markedly reduced with the twice-daily regimen (twice daily 46+/-52 vs. once daily 97+/-60 microg/day, P < 0.001). We conclude that a twice-daily PTH regimen provides effective treatment of hypoparathyroidism and reduces the variation in serum calcium levels at a lower total daily PTH dose.
登录
查看更多内容
DOI:
10.1016/s0022-3476(85)80668-5
发表时间:
1985
期刊:
The Journal of pediatrics
影响因子:
--
作者:
Chan,JC;Young,RB;Hartenberg,MA;Chinchilli,VM
通讯作者:
Chinchilli,VM
影响因子:
8
作者:
Chan,JC;Young,RB;Alon,U;Mamunes,P
通讯作者:
Mamunes,P
DOI:
10.1210/jcem-55-4-727
发表时间:
1982
期刊:
The Journal of clinical endocrinology and metabolism
影响因子:
--
作者:
Markowitz,ME;Rosen,JF;Smith,C;DeLuca,HF
通讯作者:
DeLuca,HF
DOI:
10.1210/edrv-17-4-289
发表时间:
1996
期刊:
Endocrine reviews.
影响因子:
--
作者:
Chattopadhyay,N;Mithal,A;Brown,EM
通讯作者:
Brown,EM
DOI:
10.1210/jcem.77.6.8263137
发表时间:
1993
期刊:
The Journal of clinical endocrinology and metabolism
影响因子:
--
作者:
Lindsay,R;Nieves,J;Henneman,E;Shen,V;Cosman,F
通讯作者:
Cosman,F